Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The search term “GLP 3 peptide” (also written GLP3 peptide or GLP-3 peptide) has become shorthand for a specific class of research compound: a single synthetic peptide engineered to activate three class B G-protein-coupled receptors at once, the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). There is no naturally occurring hormone called GLP-3; the label simply places the triple agonist after the GLP-1 mono-agonist and the GLP-1/GIP dual agonist in a numbered research family. Within the Rejuven8 catalog that compound carries the coded designation GLP-3 RT.
This article reviews where the literature on triple receptor agonism stands in 2026: the structural biology that explains how one peptide engages three receptors, the rodent and cell-model work accumulated through 2025 and 2026, and how clinical-stage publications on pharmaceutical triple agonists are read from a laboratory perspective. Everything here is framed for research use only, not for human consumption, and reflects experimental observations rather than any endorsed application.
GLP 3 Peptide: What the Name Means and What the Molecule Is
A naming convention, not a hormone
The incretin research family is often described in tiers. The first is mono-agonism at GLP-1R, represented in coded form by GLP-1 SM. The second is dual agonism at GLP-1R and GIPR, represented by GLP-2 TZ. The third adds the glucagon receptor, and that is the compound loosely called the GLP-3 peptide. The numbering describes the order in which receptor combinations were developed, not a biological series of hormones: native GLP-2 is an intestinal peptide unrelated to GLP-2 TZ, and there is no native GLP-3 at all.
Molecular identity of GLP-3 RT
GLP-3 RT is built on a modified GIP-derived backbone with helix-stabilizing substitutions and a fatty diacid attached through a linker to a lysine side chain, a design that supports reversible albumin binding in animal pharmacokinetic work. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Designation | GLP-3 RT (coded research designation) |
| Class | Acylated multi-receptor (triple) incretin agonist peptide |
| Sequence length | 39 amino acids |
| Approx. molecular weight | ~4731 Da (about 4.7 kDa) |
| Receptor targets | GLP-1R, GIPR, GCGR (all class B GPCRs) |
| Lipidation | Fatty diacid attached via linker to a lysine residue |
| Primary assay readout | Gs-coupled cyclic AMP (cAMP) accumulation |
Because identity and purity determine whether receptor assays are interpretable, a lot-specific certificate of analysis with HPLC and mass-spectrometry data is the starting document for any such work; the guide to reading a peptide COA explains how those values are reported.
Structural Biology: How One Peptide Engages Three Receptors
How can a single 39-residue chain be recognized by three receptors whose native ligands differ? A 2024 cryo-electron microscopy study in Cell Discovery addressed this directly by solving the triple agonist in complex with each receptor and its heterotrimeric Gs protein.
A continuous helix with two jobs
In all three complexes the peptide adopts a single continuous alpha helix. Its N-terminal segment inserts into the receptor transmembrane core, the region that triggers G-protein coupling, while its C-terminal segment lies along the N-terminal helix of the extracellular domain, the region that provides binding affinity. This two-domain binding mode is the hallmark of class B GPCR peptide recognition.
Where the receptors differ
The backbone positions of the three complexes are strikingly similar, yet each receptor accommodates the peptide through different local features. At GLP-1R and GCGR the first extracellular loop (ECL1) forms a rigid helical segment, whereas at GIPR the same loop is flexible because of proline residues, which lets the peptide align differently in the upper binding pocket. Conserved salt bridges and hydrogen bonds anchor the peptide at shared residues, while variable contacts in ECL1, ECL2, and the first transmembrane helix account for the balance of activity among the three. Selectivity, in other words, is tuned in the upper pocket rather than at the conserved core.
Preclinical Literature: What Animal and Cell Models Have Shown
Glucagon signaling in hepatocytes and adipose tissue is studied for its influence on energy expenditure and lipid oxidation, while GLP-1R and GIPR signaling are studied for glucose-dependent insulin secretion and central effects on food intake. The literature since 2022 has asked whether one molecule carrying all three arms changes the metabolic picture in rodents in ways mono-agonism does not.
Body weight and body composition in obese rodents
A 2022 study in Molecular Metabolism reported that a next-generation GLP-1/GIP/glucagon triple agonist normalized body weight in diet-induced obese mice, and it remains the reference preclinical characterization of the class. More recent work has dissected each arm. A 2025 report using liver-specific glucagon receptor knockout mice found that hepatic GCGR was required for the additional body weight and metabolic effects of a dual GCGR/GLP-1R agonist over GLP-1R agonism alone. A 2026 study showed that GIPR and GCGR co-agonism, with no GLP-1R component, could restore normal body weight in obese rodents, which argues that these two arms contribute independently rather than simply amplifying GLP-1R.
Hepatic lipid metabolism
Several 2025 studies place hepatic lipid handling at the center of the field. A Nature Communications paper reported that GLP-1R/GCGR dual agonism reduced hepatic steatosis in obese male mice alongside restored insulin sensitivity and beta-cell function, and multi-omic analyses of GLP-1/GIP/GCGR tri-agonism presented in 2025 highlighted reprogramming of hepatic lipid metabolism in obese mice. Mechanistic reviews from 2025 and 2026 on metabolic dysfunction-associated steatotic liver disease (MASLD) models draw these threads together across hepatocyte, adipocyte, and whole-animal systems.
The table below maps each receptor arm to the tissues and readouts most often reported in preclinical GLP-3 peptide research. These values reflect commonly reported laboratory attributes and are provided for comparison only.
| Receptor Arm | Principal Tissues Studied | Common Preclinical Readouts | Representative Models |
|---|---|---|---|
| GLP-1R | Pancreatic islets, hypothalamus, hindbrain | cAMP accumulation, glucose-dependent insulin secretion, food intake | Beta-cell lines, diet-induced obese mice |
| GIPR | Pancreatic islets, adipose tissue, brain | cAMP accumulation, insulin secretion, adipose lipid buffering | Receptor-expressing cell lines, GIPR knockout mice |
| GCGR | Liver, adipose tissue | Hepatic glucose output, lipid oxidation, energy expenditure | Hepatocytes, liver-specific GCGR knockout mice |
| All three combined | Whole-animal metabolism | Body weight, body composition, hepatic steatosis, multi-omic profiles | Diet-induced obese mice, MASLD rodent models |
Reading the Clinical-Stage Literature from a Laboratory Perspective
Peer-reviewed clinical-stage reports on triple agonists have appeared in major journals through 2025 and 2026. A research-supply article does not summarize human outcomes, and nothing about GLP-3 RT should be read as a claim about people. What those publications offer the laboratory is narrower: confirmation that all three receptors are pharmacologically tractable in vivo with one acylated peptide, and that the receptor-balance questions raised by cryo-EM and rodent work are the ones clinical investigators are asking too. Reviews in 2025 have also set new preclinical priorities: the relative weighting of the three arms, central versus peripheral receptor contributions, and preservation of lean tissue in animal models.
For laboratories working with GLP-3 RT, these priorities translate into experimental design: pairing the triple agonist with mono- and dual-agonist comparators so each receptor arm can be isolated, and confirming identity and purity on the lot certificate before any assay. The usual peptide storage and handling guidance applies, with cold storage and minimized freeze-thaw cycles protecting the lipidated chain. GLP 3 peptide research in 2026 is best understood as a maturing preclinical field with a defined structural basis, growing receptor-specific knockout work, and open questions that a well-documented compound from the research peptide catalog can help address.
Frequently Asked Questions
What is a GLP-3 peptide?
GLP-3 peptide is informal shorthand for a synthetic triple receptor agonist that activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor with a single acylated peptide chain. It is a research compound studied in cell and animal models; its coded designation in the Rejuven8 catalog is GLP-3 RT.
Is GLP-3 a naturally occurring hormone?
No. Unlike GLP-1 and GLP-2, which are natural intestinal peptides, there is no hormone called GLP-3. The name marks the triple agonist as the third tier in a numbered research family after the GLP-1 mono-agonist and the GLP-1/GIP dual agonist.
What receptors does the GLP3 peptide act on?
The GLP3 peptide is studied for agonism at three class B G-protein-coupled receptors: GLP-1R, GIPR, and GCGR. Cryo-EM structures published in 2024 show it binding each receptor as a continuous alpha helix, with receptor-specific differences in the first extracellular loop.
What have preclinical studies of triple agonists shown?
Rodent studies have examined triple agonists for effects on body weight, body composition, hepatic steatosis, and insulin sensitivity. Receptor knockout work published in 2025 and 2026 indicates that the hepatic glucagon receptor and the GIP receptor each contribute independently beyond GLP-1 receptor agonism alone.
How does GLP-3 RT differ from GLP-1 SM and GLP-2 TZ?
GLP-1 SM is a mono-agonist at GLP-1R, GLP-2 TZ is a dual agonist at GLP-1R and GIPR, and GLP-3 RT adds the glucagon receptor to make a triple agonist. All three are acylated peptides of roughly 4 to 5 kDa used as comparators in incretin receptor research.
Is the GLP-3 peptide intended for human use?
No. GLP-3 RT is supplied for research use only, not for human consumption or self-administration. The literature summarized here describes structural, cell-based, and animal-model findings only.
References and Further Reading
- Cryo-EM structures of a triple agonist bound to GLP-1R, GIPR, and GCGR with Gs protein (Cell Discovery, 2024). PubMed: triple agonism GLP-1R GIPR GCGR cryo-EM structure
- Next-generation GLP-1/GIP/glucagon triple agonists in diet-induced obese mice (Molecular Metabolism, 2022). PubMed: GLP-1 GIP glucagon triple agonists obese mice
- Liver-specific GCGR knockout work on GCGR/GLP-1R co-agonism in mice (2025). PubMed: hepatic GCGR required GLP-1R dual agonist mice
- GIPR and GCGR co-agonism in obese rodents (2026). PubMed: GIPR GCGR co-agonism obese rodents
- GLP-1R/GCGR dual agonism, hepatic steatosis, and beta-cell function in obese mice (Nature Communications, 2025). PubMed: GLP-1R GCGR dual agonism hepatic steatosis beta-cell mice
- Mechanistic reviews of GLP-1, dual, and triple receptor agonists in MASLD models (2025-2026). PubMed: GLP-1 GIP glucagon receptor agonist MASLD mechanism review
- Poly-agonist pharmacology reviews from the Tschoep, Finan, and DiMarchi groups. PubMed: GLP-1 GIP glucagon poly-agonists review
